Rimiducid
- Generic Name
- Rimiducid
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C78H98N4O20
- CAS Number
- 195514-63-7
- Unique Ingredient Identifier
- H564L1W5J2
- Background
Rimiducid is a lipid-permeable tacrolimus analogue and a protein dimerizer. It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function. When administered via chemically-inducible dimerization (CID) technologies, rimiducid binds to switch proteins and dimerizes them, triggering downstream signaling cascade. The combination use of rimiducid with immunotherapies for enhanced therapeutic effectiveness is currently under investigation.
- Indication
Investigated for use/treatment in bone marrow transplant and graft versus host disease.
- Associated Conditions
- -
- Associated Therapies
- -
Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant
- Conditions
- Interventions
- First Posted Date
- 2018-03-08
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Bellicum Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT03459170
- Locations
- 🇮🇹
Ospedale Infantile Regina Margherita, Turin, Italy
🇮🇹San Matteo Hospital, Pavia, Italy
🇮🇹IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Bellicum Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT03301168
- Locations
- 🇺🇸
Stanford University - Division of Pediatric Stem Cell Transplant & Regenerative Medicine, Palo Alto, California, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Poseida Therapeutics, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT03288493
- Locations
- 🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸University of California San Diego, San Diego, California, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
- Conditions
- Interventions
- First Posted Date
- 2017-01-10
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT03016377
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
- Conditions
- Interventions
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- Bellicum Pharmaceuticals
- Registration Number
- NCT02786485
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Bellicum Pharmaceuticals
- Target Recruit Count
- 151
- Registration Number
- NCT02744287
- Locations
- 🇺🇸
Baylor Sammons Cancer Center, Dallas, Texas, United States
🇺🇸John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
- Conditions
- Interventions
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Bellicum Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT02743611
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
- Conditions
- Interventions
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Bellicum Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT02477878
- Locations
- 🇺🇸
Roswell Park, Buffalo, New York, United States
🇺🇸BMT Program at Northside Hospital, Atlanta, Georgia, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Bellicum Pharmaceuticals
- Target Recruit Count
- 187
- Registration Number
- NCT02065869
- Locations
- 🇮🇹
IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
🇬🇧Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom
🇬🇧Institute of Child Health & Great Ormond Street Hospital, London, United Kingdom
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Bellicum Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT01744223
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.